Kyverna Therapeutics, Inc. Other Nonoperating Income (Expense)
Kyverna Therapeutics, Inc. (KYTX) reported Other Nonoperating Income (Expense) of -$18.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-11
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was -$18.00K.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was -$21.00K.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $17.00K, a 325.00% increase year-over-year.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$53.00K.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for fiscal 2025 was -$85.00K.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for fiscal 2024 was -$90.00K.
- Kyverna Therapeutics, Inc. other nonoperating income (expense) for fiscal 2023 was -$55.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.00K 10-Q · filed 2026-08-11 | -$39.00K 10-Q · filed 2026-08-11 | -$22.00K derived: sum of 3 quarters · filed 2026-08-11 | -$75.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$21.00K 10-Q · filed 2026-05-12 | -$4.00K derived: sum of 2 quarters · filed 2026-05-12 | -$57.00K derived: sum of 3 quarters · filed 2026-05-12 | -$78.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$36.00K derived: sum of 2 quarters · filed 2026-03-26 | -$57.00K derived: sum of 3 quarters · filed 2026-08-11 | -$85.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$53.00K 10-Q · filed 2025-11-12 | -$74.00K derived: sum of 2 quarters · filed 2026-08-11 | -$102.00K 10-Q · filed 2025-11-12 | -$97.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$21.00K 10-Q · filed 2026-08-11 | -$49.00K 10-Q · filed 2026-08-11 | -$44.00K derived: sum of 3 quarters · filed 2026-08-11 | -$89.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$27.00K 10-Q · filed 2026-05-12 | -$23.00K derived: sum of 2 quarters · filed 2026-05-12 | -$68.00K derived: sum of 3 quarters · filed 2026-05-12 | -$91.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$41.00K derived: sum of 2 quarters · filed 2026-03-26 | -$64.00K derived: sum of 3 quarters · filed 2026-03-26 | -$90.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$45.00K 10-Q · filed 2025-11-12 | -$68.00K derived: sum of 2 quarters · filed 2025-11-12 | -$94.00K 10-Q · filed 2025-11-12 | -$126.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$23.00K 10-Q · filed 2025-08-12 | -$49.00K 10-Q · filed 2025-08-12 | -$81.00K derived: sum of 3 quarters · filed 2025-08-12 | -$94.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$26.00K 10-Q · filed 2025-05-13 | -$58.00K derived: sum of 2 quarters · filed 2025-05-13 | -$71.00K derived: sum of 3 quarters · filed 2025-05-13 | -$78.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$45.00K derived: sum of 2 quarters · filed 2025-03-27 | -$52.00K derived: sum of 3 quarters · filed 2025-03-27 | -$55.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$13.00K 10-Q · filed 2024-11-13 | -$20.00K derived: sum of 2 quarters · filed 2024-11-13 | -$23.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$7.00K 10-Q · filed 2024-08-12 | -$10.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$3.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |